一项关于LY3549492在健康受试者及超重或肥胖受试者中的研究
一项1期、平行设计、开放标签、随机、多剂量递增研究,旨在调查LY3549492在超重或肥胖健康受试者中的安全性、耐受性和药代动力学
The purpose of this study is to see how safe and well-tolerated the drug LY3549492 is and how it behaves in the body, when given in multiple doses to healthy people who are overweight or have obesity. Participation in the study will last approximately 8 weeks.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Florida
-
Daytona Beach、Florida、美国、32117
- Fortrea Clinical Research Unit
-
-
Texas
-
Dallas、Texas、美国、75247
- Fortrea Clinical Research Unit
-
-
Wisconsin
-
Madison、Wisconsin、美国、53704
- Fortrea Clinical Research Unit
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Have a hemoglobin A1c level of less than 6.5 percent (%) at screening.
- Have a body mass index (BMI) of 25.0 to 45.0 kilogram per square meter (kg/m²), inclusive, at screening
- Participants assigned male at birth (AMAB) or participants assigned female at birth (AFAB) who are individual of childbearing potential (INOCBP) Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion Criteria:
-
Have obesity induced by endocrine disorders such as Cushing's syndrome or Prader Willi syndrome.
-
Have any of the following conditions at screening,
- supine systolic blood pressure of 160 millimeter of mercury (mmHg) or greater
- supine diastolic blood pressure of 100 mmHg or greater, or
- resting pulse rate of greater than 95 beats per minute (bpm) or less than 45 bpm. (Note: white-coat hypertension is excluded; therefore, if a repeated measurement of blood pressure after at least 5 minutes shows values within the range, the participant can be included).
-
Have had any of the following within 6-months prior to screening
- myocardial infarction
- unstable angina
- coronary artery bypass graft
- percutaneous coronary intervention. (Note: diagnostic angiograms are permitted)
- transient ischemic attack
- cerebrovascular accident or decompensated congestive heart failure, or
- New York Health Association Class III or IV heart failure.
-
Have serum triglyceride of 5 millimoles per liter (mmol/L) or greater (442 milligrams per deciliter [mg/dL]) at screening
-
Have had any exposure to glucagon-like peptide-1 (GLP-1) analogs or other related compounds within the 3 months prior to screening
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:LY3549492 (Treatment Group 1)
LY3549492 administered orally. |
Administered orally |
|
实验性的:LY3549492 (Treatment Group 2)
LY3549492 administered orally. |
Administered orally |
|
实验性的:LY3549492 (Treatment Group 3)
LY3549492 administered orally. |
Administered orally |
|
实验性的:LY3549492 (Treatment Group 4)
LY3549492 administered orally. |
Administered orally |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
大体时间:Baseline through end of the Follow-up Period (Week 10)
|
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module |
Baseline through end of the Follow-up Period (Week 10)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3549492
大体时间:Predose on Day 1 through end of the Follow-up Period (Week 10)
|
PK: Cmax of LY3549492 |
Predose on Day 1 through end of the Follow-up Period (Week 10)
|
|
PK: Observed Drug Trough Concentration (Ctrough) of LY3549492
大体时间:Predose on Day 1 through end of the Follow-up Period (Week 10)
|
PK: Ctrough of LY3549492 |
Predose on Day 1 through end of the Follow-up Period (Week 10)
|
|
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3549492
大体时间:Predose on Day 1 through end of the Follow-up Period (Week 10)
|
PK: AUC of LY3549492 |
Predose on Day 1 through end of the Follow-up Period (Week 10)
|
合作者和调查者
调查人员
- 研究主任:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.